NorthX Biologics appoints Johanna Magnusson as Chief Operating Officer

Biopharmaceutical contract development and manufacturing organization (CDMO) NorthX Biologics is pleased to announce the appointment of Johanna Magnusson as Chief Operating Officer.

With over two decades of leadership experience in life sciences operations, production, and quality management, Johanna is a powerful addition to the NorthX Biologics team. She most recently served as Global Operations Director and Site Leader at Cavidi AB, where she was instrumental in driving strategic transformation and introducing innovative technologies to the diagnostics and pharmaceutical sectors. Prior to that, Johanna held several senior leadership roles at Cytiva (formerly GE Healthcare) in Uppsala, Sweden, where she led major production initiatives and implemented LEAN and Six Sigma methodologies to significantly enhance productivity and operational performance.

Johanna holds a Master of Science in Chemical Engineering from Umeå University, Sweden, and is a certified Six Sigma Black Belt as well as a certified Board Member through Styrelseakademin. With her international experience, she brings a global mindset to her leadership approach.

Janet Hoogstraate, CEO NorthX Biologics commented: “We are delighted to welcome Johanna. Her extensive experience in operational leadership and process excellence will be a tremendous asset as we continue to scale and expand our capabilities. Johanna’s strategic insight and collaborative approach align perfectly with our mission to deliver world-class services to our clients.”

Johanna added: “I’m excited to join NorthX Biologics at such a dynamic point in its journey. The company’s end-to-end portfolio — from microbial and mammalian recombinant proteins to viral vectors, mRNA, plasmids, cell therapy, and extracellular vesicles — is truly impressive. I look forward to working with the team to help our clients bring transformative therapies to patients around the world.” This strategic appointment reinforces NorthX Biologics’ commitment to operational excellence and innovation, as it continues to deliver cutting-edge solutions for the global biopharmaceutical industry.